Ge, L., Wang, J., Qi, W., et al. (2008) The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol induced internalization of NPC1L1. Cell Metabolism, 7, 508-519. doi:10.1016/j.cmet.2008.04.001

has been cited by the following article:

• TITLE: Ezetimibe Completely Replaced LDL-Apheresis for the Treatment of Familial Hypercholesterolemia and Coronary Artery Disease after CABG—A Case Report

  AUTHORS: Ikuo Yokoyama

  KEYWORDS: Ezetimibe; Familial Hypercholesterolemia; Statins; LDL-Apheresis; Coronary Artery Disease

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.6 No.2A, February 27, 2013

  ABSTRACT: Intensive treatment of hyperlipidemia is an important factor in the prevention of cardiovascular disease. Among several therapies, statins are well recognized as playing a central role, although low density lipoprotein bound cholesterol-apheresis can be used to treat very severe cases of familial hypercholesterolemia. However, statins are not always effective on their own and, recently, ezetimibe has emerged as a unique anti- hypercholesterolemic drug that acts as a cholesterol transporter inhibitor; its role is only partially understood. I experienced rare case that appeared to benefit from ezetimibe therapy, and report them as they help increase our knowledge of this novel drug.